Dulaglutide Outperforms Liraglutide for Blood Sugar Control in Real-World Diabetes Care | Research

The takeaway

In a real-world study of 2,418 type 2 diabetes patients, dulaglutide reduced HbA1c more than liraglutide (-0.24% difference), with similar effectiveness to exenatide once weekly.

-0.24% HbA1c advantage
Dulaglutide reduced HbA1c significantly more than liraglutide in real-world clinical practice

What the researchers found

Dulaglutide reduced HbA1c 0.24% more than liraglutide in real-world clinical practice (p=0.003), confirmed by meta-analysis of observational studies.

Why it matters

Real-world data often differs from clinical trials. This study helps clinicians choose between GLP-1 drugs based on actual patient outcomes in routine care, not just idealized trial settings.

The numbers in context

Dulaglutide vs liraglutide: -0.24% HbA1c (p=0.003); meta-analysis vs exeOW: -0.19% HbA1c (p=0.003), -0.8 kg (p=0.007); 5.9 month follow-up

How the study worked

Retrospective multicenter real-world study (2010-2018) with propensity score matching, plus meta-analysis of similar observational studies covering the same drug comparisons.

Who was studied

2,418 type 2 diabetes patients at specialist clinics (849 dulaglutide, 1,371 liraglutide, 198 exenatide OW) from 2010-2018

What this study cannot tell us

Observational design with potential residual confounding; liraglutide under-dosing likely influenced results; exenatide group was small (n=198); short follow-up of ~6 months.

How to read the evidence

Large real-world study with propensity score matching and supporting meta-analysis, but observational design cannot fully eliminate confounding.

When this study was published

Published in 2020; the GLP-1 RA landscape has since expanded with semaglutide becoming a dominant option not included in this comparison.

The bigger picture

As GLP-1 receptor agonists become first-line diabetes treatments, head-to-head real-world comparisons help guide clinical decision-making beyond what controlled trials alone can show.

Questions still open

Would dulaglutide still outperform liraglutide if all patients received optimal dose titration?
How do these real-world comparisons change with semaglutide added to the analysis?
Do the HbA1c differences translate to meaningful differences in cardiovascular or mortality outcomes?

Common questions

Is dulaglutide better than liraglutide for diabetes?

In real-world practice, dulaglutide reduced HbA1c 0.24% more than liraglutide, though this may partly reflect liraglutide under-dosing rather than inherent drug superiority.

What is HbA1c and why does it matter?

HbA1c measures average blood sugar over 2-3 months. Lower HbA1c means better diabetes control and reduced risk of complications like heart disease, kidney damage, and nerve problems.

Read the original research

Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.

Metabolism: clinical and experimental, 106, 154190

View on PubMed ↗Publisher’s paper ↗

Citation

Morieri, Mario Luca; Rigato, Mauro; Frison, Vera; Simioni, Natalino; D'Ambrosio, Michele; Tadiotto, Federica; Paccagnella, Agostino; Lapolla, Annunziata; Avogaro, Angelo; Fadini, Gian Paolo. (2020). Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.. Metabolism: clinical and experimental, 106, 154190. https://doi.org/10.1016/j.metabol.2020.154190